Should I buy Arcus Biosciences, Inc. (RCUS) stock or is it too late?

Arcus Biosciences, Inc. · Health Care · price $23

See the full Arcus Biosciences, Inc. (RCUS) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 60% of its targets hit on this sector (329 calls tested). It aims for $45 (+100 %), call made on July 21, 2026, maturing on July 21, 2027 (85 d ago).

The 1 reliable analyst $45+100 %

The 6 other firms $37+64 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $45 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Arcus Biosciences, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Morgan Stanley	57 %	+55.2 %	7	$22 -2%
Barclays	43 %	+24.3 %	7	$14 -38%
Mizuho	33 %	+5.1 %	6	$42 +87%
Cantor Fitzgerald	25 %	+0.7 %	8	$36 +60%
Truist Securities	20 %	-17.5 %	5	$40 +78%
Citigroup	11 %	-24.8 %	9	$45 +100%
Wedbush	0 %	-27.5 %	8	$43 +91%
SVB Leerink	40 %	-4.2 %	10	—

In short — Should you invest in Arcus Biosciences, Inc.? Is it too late, still worth it? Analysts are fairly positive (75% buy, median target $40, i.e. +78%), and the most reliable on RCUS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
Median price target $40, i.e. +78% from the current price ($23).
The most reliable firm on RCUS, Wells Fargo (67% hit rate, 3 scored calls), targets $26 (call made on August 6, 2026, maturing on August 6, 2027) (+16%) in its most recent call, and $29 (call made on October 20, 2025, maturing on October 20, 2026) (+29%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on RCUS

Median target $40 (+78%) · 8 ratings · Buy consensus

Strong Buy00%

Buy675%

Hold225%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Arcus Biosciences, Inc. now?

We won't decide for you. The facts: 75% of analysts rate it a buy, median target $40 (+78%), and Wells Fargo (most reliable on RCUS, 67%) targets $26. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Arcus Biosciences, Inc.?

Not according to analysts: the median target ($40) is still +78% above the current price ($23) (most reliable on RCUS: Wells Fargo, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Arcus Biosciences, Inc. still worth investing in?

It depends on the gap between the price ($23) and its estimated value: analysts target $40 on median (+78%), with 75% buys (most reliable on RCUS: Wells Fargo, 67%). Cross-check with their real reliability on RCUS and the cautions above. Information, not advice.

What's the main risk in buying RCUS?

The consensus is not unanimous: of 8 ratings, 2 are neutral.

→ Go deeper: the full Arcus Biosciences, Inc. profile (consensus, analyst reliability, price target, performance).